Cell avidity publications
Fernandez de Larrea et al. Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma. Blood Cancer Discovery, 2020.
The z-Movi® Cell Avidity Analyzer is a solution for researchers to determine cell avidity, which has been notoriously difficult to measure until now. Through avidity measurements, the z-Movi can help researchers investigate cell interaction properties that correspond to immune cell response in a predictive, reproducible, and fast manner. All this at a high-throughput and single-cell level, without compromising cell viability.
Being able to measure these interactions provides researchers valuable information and enables them to select best candidates at an early stage. This informed selection from the start can improve their success rate dramatically.